- Home
- EWTX vs OLO Comparison
EWTX vs OLO Comparison
Compare EWTX & OLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- OLO
- Stock Information
- Founded
- EWTX 2017
- OLO 2005
- Country
- EWTX United States
- OLO United States
- Employees
- EWTX N/A
- OLO N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- OLO Major Banks
- Sector
- EWTX Health Care
- OLO Finance
- Exchange
- EWTX Nasdaq
- OLO Nasdaq
- Market Cap
- EWTX 1.2B
- OLO 1.0B
- IPO Year
- EWTX 2021
- OLO 2021
- Fundamental
- Price
- EWTX $14.58
- OLO $8.66
- Analyst Decision
- EWTX Buy
- OLO Buy
- Analyst Count
- EWTX 8
- OLO 3
- Target Price
- EWTX $40.13
- OLO $9.00
- AVG Volume (30 Days)
- EWTX 1.1M
- OLO 2.0M
- Earning Date
- EWTX 05-08-2025
- OLO 05-08-2025
- Dividend Yield
- EWTX N/A
- OLO N/A
- EPS Growth
- EWTX N/A
- OLO N/A
- EPS
- EWTX N/A
- OLO 0.01
- Revenue
- EWTX N/A
- OLO $299,107,000.00
- Revenue This Year
- EWTX N/A
- OLO $19.60
- Revenue Next Year
- EWTX N/A
- OLO $17.69
- P/E Ratio
- EWTX N/A
- OLO $446.03
- Revenue Growth
- EWTX N/A
- OLO 23.31
- 52 Week Low
- EWTX $10.60
- OLO $4.20
- 52 Week High
- EWTX $38.12
- OLO $9.78
- Technical
- Relative Strength Index (RSI)
- EWTX 43.22
- OLO 60.06
- Support Level
- EWTX $13.80
- OLO $8.44
- Resistance Level
- EWTX $14.68
- OLO $9.27
- Average True Range (ATR)
- EWTX 0.78
- OLO 0.36
- MACD
- EWTX 0.08
- OLO -0.10
- Stochastic Oscillator
- EWTX 29.68
- OLO 19.78
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.